Consultation has opened for the July 2023 Pharmaceutical Benefits Advisory Committee (PBAC) agenda.
The PBAC welcomes input from patients, carers, health professionals, consumer groups or organisations and members of the public on medicines submitted for PBAC consideration.
The PBAC considers these public consultation inputs when considering the clinical and economic evidence presented by the applicant.
Providing input on more than one medicine? You will need to complete a separate survey for each medicine. Alternatively, email your input to commentsPBAC@health.gov.au
Please note that in the last question we welcome your comments and suggestions on ways to improve the survey and this process. All responses are considered after each round of consultation, and improvements are then made to the survey and its guidance where appropriate.
PBAC Outcomes are published to inform the public about the PBAC’s advice to the Minister for Health. The documents report the PBAC’s recommendation in each case and summarise the reasons for the advice.
The PBAC outcomes are available on the PBS website six (6) weeks after each PBAC meeting and can be found using the Medicine Status Website.
Further explanation of the PBAC outcome and input received is available in the Public Summary Document. Public Summary Documents are available on the PBS website approximately four (4) months after the PBAC meeting. See the PBAC calendar for publication dates.
Share
Share on Twitter Share on Facebook